Grupo Argentino de Tumores Estromales Digestivos GATE D

Buenos Aires, Argentina

Grupo Argentino de Tumores Estromales Digestivos GATE D

Buenos Aires, Argentina

Time filter

Source Type

Chacon M.,Grupo Argentino de Tumores Estromales Digestivos GATE D | Eleta M.,Grupo Argentino de Tumores Estromales Digestivos GATE D | Espindola A.R.,Grupo Argentino de Tumores Estromales Digestivos GATE D | Roca E.,Grupo Argentino de Tumores Estromales Digestivos GATE D | And 3 more authors.
Future Oncology | Year: 2015

Introduction: Imatinib is the standard first-line therapy for advanced gastrointestinal stromal tumor. 18F-fluorodeoxyglucose PET computed tomography (FDG PET/CT) shows a faster response than computed tomography in nonpretreated patients. Patients & methods: After disease progression on imatinib 400 mg, 16 patients were exposed to 800 mg. Tumor response was evaluated by FDG PET/CT on days 7 and 37. Primary objective was to correlate early metabolic response (EMR) with progression-free survival (PFS). Results: EMR by FDG PET/CT scan was not predictive of PFS. Median PFS in these patients was 3 months. Overall survival was influenced by gastric primary site (p = 0.05). Conclusion: The assessment of EMR by FDG PET/CT in patients with advanced gastrointestinal stromal tumor exposed to imatinib 800 mg was not predictive of PFS or overall survival. © 2015 Future Medicine Ltd.


PubMed | Grupo Argentino de Tumores Estromales Digestivos GATE D
Type: Journal Article | Journal: Future oncology (London, England) | Year: 2015

Imatinib is the standard first-line therapy for advanced gastrointestinal stromal tumor. (18)F-fluorodeoxyglucose PET computed tomography (FDG PET/CT) shows a faster response than computed tomography in nonpretreated patients.After disease progression on imatinib 400 mg, 16 patients were exposed to 800 mg. Tumor response was evaluated by FDG PET/CT on days 7 and 37. Primary objective was to correlate early metabolic response (EMR) with progression-free survival (PFS).EMR by FDG PET/CT scan was not predictive of PFS. Median PFS in these patients was 3 months. Overall survival was influenced by gastric primary site (p = 0.05).The assessment of EMR by FDG PET/CT in patients with advanced gastrointestinal stromal tumor exposed to imatinib 800 mg was not predictive of PFS or overall survival.

Loading Grupo Argentino de Tumores Estromales Digestivos GATE D collaborators
Loading Grupo Argentino de Tumores Estromales Digestivos GATE D collaborators